ADG-2e
ADG-2e is a potent antibacterial agent with MICs of 16, 4, 2, and 2 μg/mL for E. coli [KCTC 1682], P. aeruginosa [KCTC 1637], B.subtilis [KCTC 3068], and S. aureus [KCTC 1621], respectively. ADG-2e shows anti-metastatic activity against breast cancer cells.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 2419951-75-8
- 分子式: C42H67N11O4
- 分子量:790.05
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
Antibiotic アイソフォーム固有の製品をすべて表示
More
生物活性
製品説明
体外実験
ADG-2e (1-64 μg/mL, 22 hours) exhibits twice the antibacterial activity compared to other antibiotics in methicillin-resistant S. aureus (MRSA) or multidrug-resistant P. aeruginosa (MDRPA) [1]. ADG-2e (0-60 μg/mL, 2 hours) shows only slight hemolysis with increasing concentration[1]. ADG-2e (0-100 μM, 24 hours) does not inhibit the proliferation of MDA-MB-231 cells but has a role in the migration of cancer cells by inserting into the surface of them and affecting cell motility[1]. ADG-2e (0-40 μM, 6 hours) causes actin reorganization to promote its multiple lamellar structures formation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Sheep red blood cells (sRBCs)
-
Concentration:0-60 μg/mL
-
Incubation Time:2 hours
-
Result:Showed any hemolysis until 16 μg/mL and showed slight hemolysis at 32 μg/mL.
-
Cell Line:Metastatic breastcancer cell line MDA-MB-231
-
Concentration:0-100 μM
-
Incubation Time:24 hours
-
Result:No significant inhibitory effect on the proliferation of MDA-MB-231 cells.
-
Cell Line:Metastatic breastcancer cell line MDA-MB-231
-
Concentration:0-40 μM
-
Incubation Time:6 hours
-
Result:Showed an increase in actin lamellipodium generation.
化学情報
-
CAS 番号 2419951-75-8
-
分子量 790.05
-
分子式 C42H67N11O4
-
SMILES
CC1=CN([C@H]2C[C@H](NC(CC34C[C@@H]5C[C@H](C3)C[C@H](C4)C5)=O)[C@@H](CNC(CC67C[C@@H]8C[C@H](C6)C[C@H](C7)C8)=O)O2)C(N=C1N(CCCNC(N)=N)CCCNC(N)=N)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
プロトコル
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
純度とドキュメンテーション
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)